{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:14:09Z","timestamp":1788016449541,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T00:00:00Z","timestamp":1633305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Anlage eines transurethralen Dauerkatheters (DK) oder suprapubischen Harnblasenkatheters (SPK) in lebenslanger Indikation stellt einen Eingriff mit relevanten Komplikationen, Komorbidit\u00e4ten und m\u00f6glichen Auswirkungen auf die katheterassoziierte Lebensqualit\u00e4t des Betroffenen dar. Letztere wurde aber bisher noch nicht untersucht.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Zur Anwendung kam ein validiertes Assessment zur katheterbezogenen Lebensqualit\u00e4t mit 25\u00a0Items in 5\u00a0Dom\u00e4nen. Befragt wurden im Rahmen eines Katheterwechsels Patienten mit einem DK oder SPK in lebenslanger Intention, die diesen mindestens 3\u00a0Monate trugen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Frageb\u00f6gen von 357\u00a0Patienten, davon 260\u00a0M\u00e4nner und 97\u00a0Frauen, 193 mit SPK und 162 mit DK (2\u00a0ohne Angabe) lagen vor. Patienten mit DK waren mit 78,9\u202f\u00b1\u200911,1\u00a0Jahren signifikant \u00e4lter als solche mit SPK mit 74,4\u202f\u00b1\u200912,6\u00a0Jahren (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090,001). Der mittlere Gesamtlebensqualit\u00e4tsscore lag bei 4,1\u202f\u00b1\u20090,9\u00a0Punkten auf einer Skala von\u00a01 (maximal beeintr\u00e4chtigte Lebensqualit\u00e4t) bis\u00a05 (keine Beeintr\u00e4chtigung der Lebensqualit\u00e4t). Es zeigten sich u.\u202fa. mit niedrigeren Scores eine vermehrte Angst vor Katheterlecks, Angst vor Uringeruch und Harnwegsinfektionen und vor schmerzhaften Katheterwechseln. Diese Sorgen waren v.\u202fa. bei Frauen, solchen mit Harninkontinenz, Tr\u00e4gern eines Katheters \u2265\u202f18\u00a0Ch und bei Patienten &lt;\u202f70\u00a0Jahren vorhanden. Frauen mit einem SPK wiesen eine schlechtere Bewertung ihrer Lebensqualit\u00e4t als M\u00e4nner mit SPK auf.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die gefundenen Ergebnisse sollten in die Aufkl\u00e4rung zu einer lebenslangen Katheterableitung  einflie\u00dfen bzw. im Kontext m\u00f6glicher Alternativen wie z.\u202fB. einer operativen Desobstruktion oder einer Hilfsmittelversorgung mit dem Patienten bzw. Betreuungspersonen besprochen werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00120-021-01642-1","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T03:39:57Z","timestamp":1633405197000},"page":"18-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lebensqualit\u00e4t bei Tr\u00e4gern eines suprapubischen oder transurethralen Harnblasenkatheters als lebenslange Dauerversorgung","Quality of life for wearers of a suprapubic or transurethral bladder catheter as lifelong permanent care"],"prefix":"10.1007","volume":"61","author":[{"given":"A.","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gedding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Heese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kirschner\u2011Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Karstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Eisenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bannowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Linn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wirz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2011J.","family":"Heppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00120-019-0883-8","volume":"58","author":"A Wiedemann","year":"2019","unstructured":"Wiedemann\u00a0A, Kirschner-Hermanns\u00a0R, Heppner\u00a0HJ (2019) Palliative long-term urinary bladder drainage: the uro-geriatric point of view. Urologe\u00a0A 58:389\u2013397","journal-title":"Urologe A"},{"key":"1642_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/a-1011-4919","volume":"51","author":"A Wiedemann","year":"2020","unstructured":"Wiedemann\u00a0A, Becher\u00a0K, Bojack\u00a0B, Drews\u00a0C, Ege\u00a0S et\u00a0al (2020) S2e guideline \u201eUrinary incontinence in geriatric patients\u201c: a\u00a0summary. Aktuelle Urol 51:65\u201370","journal-title":"Aktuelle Urol"},{"key":"1642_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1055\/a-0736-3722","volume":"50","author":"A Wiedemann","year":"2019","unstructured":"Wiedemann\u00a0A, Puttmann\u00a0J, Heppner\u00a0H (2019) The ISAR-positive patient in urology. Aktuelle Urol 50:100\u2013105","journal-title":"Aktuelle Urol"},{"issue":"1","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/a-0942-9276","volume":"51","author":"M Knoblauch","year":"2019","unstructured":"Knoblauch M, Wiedemann A, Heppner HJ (2019) Is it possible to avoid a\u00a0life-long suprapubic catheter in geriatric patients with urinary retention or overflow incontinence by a\u00a0simultaneous GreenLight laser procedure? Aktuelle Urol 51(1):42\u201347. https:\/\/doi.org\/10.1055\/a-0942-9276","journal-title":"Aktuelle Urol"},{"key":"1642_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1308\/003588406X95101","volume":"88","author":"RS Ahluwalia","year":"2006","unstructured":"Ahluwalia\u00a0RS, Johal\u00a0N, Kouriefs\u00a0C, Kooiman\u00a0G, Montgomery\u00a0BS, Plail\u00a0RO (2006) The surgical risk of suprapubic catheter insertion and long-term sequelae. Ann R Coll Surg Engl 88:210\u2013213","journal-title":"Ann R Coll Surg Engl"},{"key":"1642_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1464-410X.2011.10882.x","volume":"110","author":"P Jacob","year":"2012","unstructured":"Jacob\u00a0P, Rai\u00a0BP, Todd\u00a0AW (2012) Suprapubic catheter insertion using an ultrasound-guided technique and literature review. BJU Int 110:779\u2013784","journal-title":"BJU Int"},{"key":"1642_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.juro.2016.05.114","volume":"196","author":"NF Davis","year":"2016","unstructured":"Davis\u00a0NF, Quinlan\u00a0MR, Bhatt\u00a0NR, Browne\u00a0C, MacCraith\u00a0E et al (2016) Incidence, cost, complications and clinical outcomes of iatrogenic urethral catheterization injuries: a prospective multi-institutional study. J\u00a0Urol 196:1473\u20131477","journal-title":"J Urol"},{"key":"1642_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/SPV.0000000000000249","volume":"22","author":"P Kandadai","year":"2016","unstructured":"Kandadai\u00a0P, Duenas-Garcia\u00a0OF, Pilzeck\u00a0AL, Saini\u00a0J, Flynn\u00a0MK et al (2016) A randomized controlled trial of patient-controlled valve catheter and indwelling foley catheter for short-term bladder drainage. Female Pelvic Med Reconstr Surg 22:88\u201392","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"1642_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00192-016-3164-8","volume":"28","author":"MM Takase-Sanchez","year":"2017","unstructured":"Takase-Sanchez\u00a0MM, Thompson\u00a0JC, Hale\u00a0DS, Heit\u00a0MH (2017) Suprapubic versus transurethral bladder drainage following reconstructive pelvic surgery: a\u00a0comparison of patient satisfaction and quality of life. Int Urogynecol\u00a0J 28:721\u2013728","journal-title":"Int Urogynecol J"},{"key":"1642_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1442-2042.2012.02980.x","volume":"19","author":"S Orikasa","year":"2012","unstructured":"Orikasa\u00a0S, Kanbe\u00a0K, Shirai\u00a0S, Shintaku\u00a0I, Kurosu\u00a0S (2012) Suprapubic versus transurethral bladder drainage after radical prostatectomy: impact on patient discomfort. Int J Urol 19:587\u2013590","journal-title":"Int J Urol"},{"key":"1642_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/nau.22812","volume":"35","author":"RS Lavelle","year":"2016","unstructured":"Lavelle\u00a0RS, Coskun\u00a0B, Bacsu\u00a0CD, Gliga\u00a0LA, Christie\u00a0AL, Lemack\u00a0GE (2016) Quality of life after suprapubic catheter placement in patients with neurogenic bladder conditions. Neurourol Urodyn 35:831\u2013835","journal-title":"Neurourol Urodyn"},{"key":"1642_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sc.2011.94","volume":"50","author":"R Bothig","year":"2012","unstructured":"Bothig\u00a0R, Hirschfeld\u00a0S, Thietje\u00a0R (2012) Quality of life and urological morbidity in tetraplegics with artificial ventilation managed with suprapubic or intermittent catheterisation. Spinal Cord 50:247\u2013251","journal-title":"Spinal Cord"},{"key":"1642_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/WON.0000000000000069","volume":"41","author":"S Fowler","year":"2014","unstructured":"Fowler\u00a0S, Godfrey\u00a0H, Fader\u00a0M, Timoney\u00a0AG, Long\u00a0A (2014) Living with a\u00a0long-term, indwelling urinary catheter: catheter users\u2019 experience. J\u00a0Wound Ostomy Continence Nurs 41:597\u2013603","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"1642_CR14","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/nau.22356","volume":"32","author":"KF Hunter","year":"2013","unstructured":"Hunter\u00a0KF, Bharmal\u00a0A, Moore\u00a0KN (2013) Long-term bladder drainage: suprapubic catheter versus other methods: a\u00a0scoping review. Neurourol Urodyn 32:944\u2013951","journal-title":"Neurourol Urodyn"},{"key":"1642_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/nau.20865","volume":"29","author":"MH Wilde","year":"2010","unstructured":"Wilde\u00a0MH, Getliffe\u00a0K, Brasch\u00a0J, McMahon\u00a0J, Anson\u00a0E, Tu\u00a0X (2010) A new urinary catheter-related quality of life instrument for adults. Neurourol Urodyn 29:1282\u20131285","journal-title":"Neurourol Urodyn"},{"key":"1642_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0090-4295(98)00454-3","volume":"53","author":"DL Patrick","year":"1999","unstructured":"Patrick\u00a0DL, Martin\u00a0ML, Bushnell\u00a0DM, Yalcin\u00a0I, Wagner\u00a0TH, Buesching\u00a0DP (1999) Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 53:71\u201376","journal-title":"Urology"},{"key":"1642_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2318-13-46","volume":"13","author":"KF Hunter","year":"2013","unstructured":"Hunter\u00a0KF, Voaklander\u00a0D, Hsu\u00a0ZY, Moore\u00a0KN (2013) Lower urinary tract symptoms and falls risk among older women receiving home support: a\u00a0prospective cohort study. BMC Geriatr 13:46","journal-title":"BMC Geriatr"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:03:58Z","timestamp":1642417438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,4]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01642-1","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,4]]},"assertion":[{"value":"18 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A. Wiedemann gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Dr. Pfleger, Pfizer Pharma, Omega Pharma; Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board): Dr. Pfleger, Pfizer Pharma, Omega Pharma; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: AMS Deutschland, Astellas, Berlin Chemie, Boston Scientific, Dr. Pfleger, Ipsen, Jansen, Meda, Omega Pharma, Acticor, Aristo; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: Boston Scientific, Dr. Pfleger, Paul-Kuth-Stiftung Deutsche Bank; indirekte Interessen: DGU, DGG, DKG, NRW-GU. J. Stein gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Advisory Board der Firma Bayer; Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board): Advisory Board der Firma Bayer; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Medac, Lilly; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: Medac, Lilly, Jenapharm, Boston Scientific, Pfizer, Takeda, Astellas, Janssen, Sanofi, Dr. Pfleger, Gruenenthal, MSD, Bristol-Myers-Squibb. A. Manseck gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Bayrische Landes\u00e4rztekammer, Landesdirektion Sachsen, OnkoZert; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: DGU, BvDU, Garmisches Assistentenseminar; indirekte Interessen: Geriatrische Urologie, robotische Urologie, DGU, Bayerische Urologenvereinigung, Roboter-Assistierte Urologie, F\u00f6rderverein Krebskranker der Region Ingolstadt e.\u202fV. R. Kirschner-Hermanns gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: CEO und Founder der MEC\/\/ABC GmbH, Medical Care and Product development in Aachen, Bonn und Cologne; Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board): CEO und Founder der MEC\/\/ABC GmbH, Medical Care and Product development in Aachen, Bonn und Cologne; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Repha GmbH; bezahlte Autoren-\/oder Koautorenschaft: CEO und Founder der MEC\/\/ABC GmbH, Medical Care and Product development in Aachen, Bonn und Cologne; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: Forschung: Angocei Antinfekt <i>N, <\/i>Schulung f\u00fcr Laborie F\u00f6rderverein Kontinenzf\u00f6rderung und Kontinenzaufkl\u00e4rung e.V. Aachen; Eigent\u00fcmerinteressen (Patent, Urheberrecht, Aktienbesitz): Aktie, 100\u202f% Anderl.; indirekte Interessen: DAU, DGU, DGG. A.\u00a0Schorn gibt an: indirekte Interessen: DGU. A. Wagner gibt an: indirekte Interessen: DGU. V. Moll gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Recordati; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Recordati, Aristo, Medac. A. Eisenhardt gibt an: bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Takeda, Apogepha, Medac, Janssen-Cilag und Ipsen; indirekte Interessen: DGU. A. Bannowsky gibt an: indirekte Interessen: DGU. C.\u00a0Linn\u00e9 gibt an: Berater- und Gutachter-T\u00e4tigkeit: Apogepha Pharma GmbH; Mitarbeit in einem Wissenschaftlichen Beirat: Apogepha Pharma GmbH, Janssen Csilag, MSD, BMS; Bezahlte Vortragst\u00e4tigkeit: MSD, ratiopahrm, IBSEN, Apogepha, Pfizer, BMS; bezahlte Autoren-\/oder Co-Autorenschaft: (noch) keine; Forschungsvorhaben\/Durchf\u00fchrung Klinischer Studien: derzeit keine; Eigent\u00fcmer-Interessen: keine; Indirekte Interessen: keine. S.\u00a0Wirz gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Dr. Pfleger, Stada Pharma, KyowaKirin, Sandoz\/Hexal; Mitarbeit in einem Wissenschaftlichen Beirat (Advisory Board): Dr. Pfleger, Stada Pharma, KyowaKirin, Sandoz\/Hexal; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: KyowaKirin, Gr\u00fcnenthal, Dr. Kade\/Besin, Mundipharma China. H.\u2011J. Heppner gibt an: Berater- bzw. Gutachtert\u00e4tigkeit: Astellas Pharma, Pfizer Pharma; bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Pfizer Pharma, Bayer Health Care, Mundipharma, Astellas Pharma, MSD, BL\u00c4K, AO Trauma Europa; Forschungsvorhaben\/Durchf\u00fchrung klinischer Studien: ThermoScience, Forschungskolleg Geriatrie der Robert-Bosch-Stiftung, Wissenschaftsforum Geriatrie, Infectopharm; GBA Innovationsfonds. C.\u00a0Gedding, M.\u00a0Heese, H.\u00a0Karstedt, A.\u00a0Schorn, A.\u00a0Wagner, U.\u00a0Unger, A.\u00a0Bannowsky und E.\u00a0Brammen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}